TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~If a patient does not meet any exclusion criteria and to be undergone double-J stent indwelling.~Exclusion Criteria:~1. Prior history of pelvic surgery~2. Prior history of Transurethral Resection of the either Prostate or Bladder Tumor~3. Benign prostate hyperplasia~4. Recent or recurrent urinary tract infection~5. Chronic medication with beta-blockers or Anti-cholinergic~6. Pregnancy~7. Prostatitis~8. Prostate cancer~9. Bilateral ureteroscopy or ureteral stenting~10. Age \< 18 and \> 55~11. Stone size \> 20 mm~12. Diabetes~13. Bladder Outlet Obstruction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Terazosin (Type: ACTIVE_COMPARATOR): None
- Tolterodine (Type: ACTIVE_COMPARATOR): None
- Tolterodine + Terazosin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged at least 18 years that has been newly prescribed adalimumab therapy according to the local product label, with the first dose corresponding to the Enrollment/Baseline visit.~* Patient with a diagnosis of moderate to severe RA, who has had insufficient response to one or more disease-modifying antirheumatic drugs (DMARDs), and has a prescription of adalimumab according to the local regulations.~* Patients should be evaluated for tuberculosis (TB) exposure/risk factors for active and latent TB (per local requirements and according to the local product label).~* Patients must be able and willing to provide written authorization to disclose and use personal health information (and informed consent where applicable) and comply with the requirements of this study protocol as well as agree to data being collected and provided to AbbVie.~Exclusion Criteria:~* Patients should not be enrolled if they cannot be treated in accordance with the local adalimumab product label.~* Patients treated with \> 1 prior biologic DMARD for RA. Any prior treatment with adalimumab is prohibited.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Participants With RA Receiving Adalimumab (Type: None): Participants with RA who were prescribed adalimumab based on current clinical practice criteria (regardless of participation in the study), with the first dose corresponding to the Enrollment/Baseline visit.~All participants were offered to participate in the PSP while treated with ADA for their RA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (most important):~* ASD (autistic disorder or Asperger's disorder or Pervasive Developmental Disorder - Not Otherwise Specified \[PDD NOS\])~* Criteria A through D for Attention-Deficit/Hyperactivity Disorder (ADHD)~* At least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating Scale-IV-Parent Version~* Intelligence quotient (IQ) score \> 60~Exclusion Criteria (most important):~* weight under 20 kg~* Patients who meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) criteria for ASD other than Autistic Disorder, PDD-NOS or Asperger's Disorder;history of Bipolar I or II disorder, schizophrenia, another psychotic disorder, substance abuse;Have a significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, or seizure disorder identified by history, physical examination, or laboratory tests; Patients who have taken (or are currently taking) anticonvulsants for seizure control.~* patients at serious suicidal risk.~* Contraindication to the use of atomoxetine~* Patients who in the investigator's judgment are likely to need psychotropic medications apart from the drug. Patients who at any time during Study Period II are likely to begin a structured psychotherapy, likely to require hospitalization (i.e. in-patient treatment) or likely to be dismissed from in-patient treatment. Psychotherapy (including hospitalization) initiated at least 2 months prior to study participation is acceptable; however, after study participation has begun, only during Study Period III supportive or educational therapy is permitted.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo every day (QD), by mouth (PO) for 8 weeks~Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a histologically confirmed diagnosis of MTC that cannot be removed by surgery, is locally advanced, or has spread in the body.~* The subject is at least 18 years old.~* The subject has an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.~* The subject has documented worsening of disease (progressive disease) at screening compared with a previous CT scan or MRI image done within 14 months of screening.~* The subject has recovered from clinically significant adverse events (side effects) due to any other medications that were administered prior to randomization.~* The subject has adequate organ and bone marrow function.~* Subjects who are sexually active (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments.~* The subject has no other diagnosis of cancer (unless non-melanoma skin cancer, an early form of cervical cancer, or another cancer diagnosed ≥ 2 years previously) and currently has no evidence of malignancy (unless non-melanoma skin cancer or an early form of cervical cancer).~* Female subjects of childbearing potential must have a negative pregnancy test at screening.~Exclusion Criteria:~* The subject has received prior treatment for their cancer within 4 weeks of randomization (6 weeks for nitrosoureas or mitomycin C).~* The subject has received radiation to ≥ 25 % of bone marrow.~* The subject has received treatment with other investigational agents (unapproved therapies) within 4 weeks of randomization.~* The subject has received treatment with XL184.~* The subject has brain metastases or spinal cord compression, unless completed radiation therapy ≥ 4 weeks prior to randomization and stable without steroid and without anti-convulsant treatment for ≥ 10 days.~* The subject has a history of clinically significant episodes of vomiting blood or a recent history of vomiting \> 2.5 mL (about 1/2 teaspoon) of red blood.~* The subject has serious illness other than cancer.~* The subject is pregnant or breastfeeding.~* The subject has an active infection requiring ongoing treatment.~* The subject is incapable of understanding and complying with the protocol or unable to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The EVARREST® Fibrin Sealant Patch Liver Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥ 18 years of age, requiring elective or urgent, open hepatic surgery.~* Presence of an appropriate bleeding hepatic parenchymal Target Bleeding Site (TBS) as identified intra-operatively by the surgeon~* Subjects or legally authorized representatives must be willing to participate in the study, and provide written informed consent. (Note: This criteria does allow for hospital translators to be used where approved by Ethics Committees/Institutional Review Boards)~Exclusion Criteria:~* Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure;~* TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of EVARREST® to blood flow and pressure during healing and absorption of the product;~* TBS with major arterial bleeding requiring suture or mechanical ligation;~* Subjects admitted for trauma surgery;~* Subject is a transplant patient for fulminant hepatic failure~* Subject with TBS within an actively infected field;~* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine;~* Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products;~* Subjects who are known, current alcohol and / or drug abusers;~* Subjects who have participated in another investigational medical device or investigational drug trial within 30 days of surgery or are expected to participate in another medical device or investigational drug trial during the course of the study;~* Female subjects who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EVARREST® Fibrin Sealant Patch (Type: EXPERIMENTAL): EVARREST® Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts - a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
- Standard of Care (SoC) (Type: OTHER): SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical. For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Moderate to severe active rheumatoid arthritis of \>/= 6 months duration~* DAS28 \>/= 3.2 at screening and baseline~* Inadequate response to biologic or non-biologic DMARDs~* Biologic DMARDs must be withdrawn (approximately 5 half-lives for the agent) before first dose of study drug~* If continuing on a non-biologic DMARD, dose should be stable for at least 8 weeks~* Oral corticosteroids must have been at stable dose for at least 25 out of 28 days prior to baseline~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or not recovered from prior surgery~* Rheumatic autoimmune disease other then RA~* Functional class IV as defined by the American College of Rheumatology (ACR) classification~* Prior history of or current inflammatory joint disease other than RA~* Previous treatment with any cell-depleting therapies~* Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline~* Active infection or history of recurrent infection~* Positive for HIV or hepatitis B or C~* History of or current primary or secondary immunodeficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trachoma Elimination Follow-up

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age 1 to 5 years old in a village in the Gurage zone with endemic trachoma~Exclusion Criteria:~Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Family Listening Program: Multi-Tribal Implementation and Evaluation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Inclusion criteria includes any families from Mescalero Apache, Jemez Pueblo and Ramah Navajo with a fourth and fifth-grade child and their parents or guardian, and grandparents who will volunteer to participate.~-~Exclusion Criteria:Those whom are ineligible in this study are: those that do not give consent and/or assent to participate; those that do not identify as tribal members of Mescalero Apache, Jemez Pueblo and Ramah Navajo or as the family member of someone that identifies as Mescalero Apache, Jemez Pueblo and Ramah Navajo; children and that are not in the targeted range of fourth and fifth grade.~-

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- Program group (Type: EXPERIMENTAL): Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
- Comparison group (Type: NO_INTERVENTION): Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Overactive Bladder Syndrome~Exclusion Criteria:~* less than 8 micturitions in 24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Histologically or cytologically confirmed adenocarcinoma of the pancreas~2. Chemo naïve patients with advanced/metastatic disease~3. Documented decision justifying non eligibility for surgical resection. The documentation of the non eligibility for surgical resection will be reviewed by an independent committee.~4. Men and women, age \>18 years~5. Men and women of childbearing potential (entering the study after a confirmed menstrual period and who have a negative pregnancy test), must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake.~6. Patient should be able and willing to comply with study visits and procedures as per protocol.~7. Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed.~Main Exclusion Criteria:~1. Patient treated for a cancer other than pancreatic cancer within 5 years before enrollment, with the exception of basal cell carcinoma or in situ cervical cancer~2. Any condition that the physician judges could be detrimental to subjects participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events Previous treatment~3. Any anti-tumor therapy (any chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy) within 6 months prior to baseline~4. Treatment with any investigational agent within 4 weeks prior to baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Masitinib & gemcitabine (Type: EXPERIMENTAL): Participants receive masitinib (9 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
- Placebo & gemcitabine (Type: PLACEBO_COMPARATOR): Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Main criteria:~* Postmenopausal women (hysterectomized or not)~* Women between 40 and 80 years of age~* Women having ≤5% of superficial cells on vaginal smear at baseline~* Women having a vaginal pH above 5 at baseline~* Women who have self-identified moderate or severe symptom(s) of vaginal atrophy~* Willing to participate in the study and sign an informed consent~Exclusion Criteria:~Main criteria:~* Previous enrollment in EndoCeutics studies performed with intravaginal DHEA~* Previous diagnosis of cancer, except skin cancer (non melanoma)~* Clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by medication~* The administration of any investigational drug within 30 days of screening visit~* Clinically significant abnormal serum biochemistry, urinalysis or hematology

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo vaginal ovule daily for 12 weeks
- Prasterone (Type: EXPERIMENTAL): Prasterone (DHEA) vaginal ovule daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* Healthy male volunteers~* Body mass index between 18.0-29.9 kg/m\^2

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test Product (Type: EXPERIMENTAL): Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
- Paracetamol tablet (Type: ACTIVE_COMPARATOR): Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete